Results of a safety review have led to the discontinuation of phase 3 clinical studies of elenbecestat, an investigational oral BACE (beta amyloid cleaving enzyme) inhibitor, which was being assessed for early Alzheimer disease (AD) treatment.
Both studies randomized a total of ~2100 patients with mild cognitive impairment or mild AD who had confirmed amyloid pathology in the brain, to receive either elenbecestat 50mg or placebo daily during the treatment period of 24 months; Clinical Dementia Rating-Sum of Boxes score was designated as the primary end point in both trials.
Additional data from the studies will be presented at future medical meetings, according to the Companies. A long-term extension trial evaluating elenbecestat will also be discontinued.
For more information visit eisai.com.
This article originally appeared on MPR